Frontiers of Medicine最新文献

Precision medicine for advanced biliary tract cancer in China: current status and future perspectives. 中国晚期胆道癌的精准医疗：现状与未来展望

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-10-15 DOI: 10.1007/s11684-025-1144-4

Zhen Huang, Wen Zhang, Yongkun Sun, Dong Yan, Xijie Zhang, Lu Liang, Hong Zhao

{"title":"Precision medicine for advanced biliary tract cancer in China: current status and future perspectives.","authors":"Zhen Huang, Wen Zhang, Yongkun Sun, Dong Yan, Xijie Zhang, Lu Liang, Hong Zhao","doi":"10.1007/s11684-025-1144-4","DOIUrl":"https://doi.org/10.1007/s11684-025-1144-4","url":null,"abstract":"Biliary tract cancer (BTC) is a rare group of malignancies that develop from the epithelial lining of the biliary tree and have a poor prognosis. Although chemotherapy is the standard of care for patients with advanced BTC in China, its clinical benefits are moderate. In recent years, the approval of targeted therapies and immunotherapies has provided new avenues for the management of advanced BTC. Nonetheless, the increasing number of personalized medicine approaches has created a challenge for clinicians choosing individualized treatment strategies based on tumor characteristics. In this article, we discuss recent progress in implementing precision medicine approaches for advanced BTC in China and examine genomic profiling studies in Chinese patients with advanced BTC. We also discuss the challenges and opportunities of using precision medicine approaches, as well as the importance of considering population-specific factors and tailoring treatment approaches to improve outcomes for patients with BTC. In addition to providing a comprehensive overview of current and emerging precision medicine approaches for the management of advanced BTC in China, this review article will support clinicians outside of China by serving as a reference regarding the role of patient- and population-specific factors in clinical decision-making for patients with this rare malignancy.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Albumin-bound paclitaxel plus anlotinib in patients with recurrent, platinum-resistant primary epithelial ovarian cancer (A-Plus): a phase II, single-arm, prospective study. 白蛋白结合紫杉醇加anlotinib治疗复发性铂耐药原发性上皮性卵巢癌（a - plus）：一项II期单组前瞻性研究

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-10-01 DOI: 10.1007/s11684-025-1155-1

Yun Zhou, Jian Zhou, Yin Wang, Ji-Bin Li, Rongzhen Luo, Chanjuan Zeng, Yingxin He, Yanfang Li

{"title":"Albumin-bound paclitaxel plus anlotinib in patients with recurrent, platinum-resistant primary epithelial ovarian cancer (A-Plus): a phase II, single-arm, prospective study.","authors":"Yun Zhou, Jian Zhou, Yin Wang, Ji-Bin Li, Rongzhen Luo, Chanjuan Zeng, Yingxin He, Yanfang Li","doi":"10.1007/s11684-025-1155-1","DOIUrl":"https://doi.org/10.1007/s11684-025-1155-1","url":null,"abstract":"This study aimed to evaluate the efficacy and safety of combining albumin-bound paclitaxel (abpaclitaxel) and anlotinib for ovarian cancer. In this study, 44 patients diagnosed with platinum-resistant ovarian cancer were enrolled. Patients received ab-paclitaxel along with anlotinib until disease progression or intolerable toxicity. Efficacy was assessed according to RECIST 1.1 criteria or Rustin's criteria. The primary endpoint was the investigator-evaluated objective response rate (ORR). 44 patients were enrolled between January 2021 and March 2023 with a median age of 49 years. Twenty-nine had measurable lesions and 15 had non-measurable lesions. Overall, the investigator-evaluated ORR was 56.8% (25/44; 95% CI 0.411-0.713) in intention-to-treat population and 58.1% (25/43; 95% CI 0.422-0.726) in per-protocol population. The median progression-free survival was 9.8 months, and the median duration of response was 7.4 months. For safety, grade 3/4 adverse events (AEs) included leukopenia, gum pain, hypertension, and hand-foot syndrome. The response rates were 55.0% (11/20) in patients with previous use of antiangiogenic reagents and who had previous use of PARP inhibitors. The combination of ab-paclitaxel and anlotinib showed promising anti-tumor activity and a manageable safety profile in platinum-resistant ovarian cancer. Patients with previous use of antiangiogenic drugs or PARP inhibitors still benefited from this protocol.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perspective on strengthening dementia prevention and control system: a comprehensive framework for national health. 加强痴呆症预防和控制体系的展望：国家卫生的综合框架。

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-09-30 DOI: 10.1007/s11684-025-1154-2

Bin Cong, Hengge Xie, Yongan Sun, Jingnian Ni, Jing Shi, Mingqing Wei, Fuyao Li, Huali Wang, Luning Wang, Bin Qin, Jing Cheng, Demin Han, Wei Xiao, Boli Zhang, Jinzhou Tian

引用次数: 0

China's biosafety/biosecurity governance: evolution, challenges, and architecture design. 中国生物安全/生物安全治理：演变、挑战和架构设计。

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-09-29 DOI: 10.1007/s11684-025-1158-y

Kaiyuan Min, Yi Zhang, Jiangfeng Liu, Juntao Yang, Feng Cao, Zongchao Peng, Depei Liu

引用次数: 0

Particulate matter exposure and end-stage renal disease risk in IgA nephropathy. IgA肾病患者的颗粒物暴露与终末期肾病风险

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-09-29 DOI: 10.1007/s11684-025-1162-2

Yilin Chen, Huan Zhou, Siqing Wang, Lingqiu Dong, Yi Tang, Wei Qin

{"title":"Particulate matter exposure and end-stage renal disease risk in IgA nephropathy.","authors":"Yilin Chen, Huan Zhou, Siqing Wang, Lingqiu Dong, Yi Tang, Wei Qin","doi":"10.1007/s11684-025-1162-2","DOIUrl":"https://doi.org/10.1007/s11684-025-1162-2","url":null,"abstract":"Long-term exposure to particulate matter has been increasingly implicated in the progression of chronic kidney disease (CKD). However, its impact on IgA nephropathy (IgAN), a leading cause of end-stage renal disease (ESRD), remains unclear. A total of 1768 IgAN patients, confirmed by renal biopsy were included in this cohort study. Long-term exposure to PM2.5 and PM10 was assessed using high-resolution satellite-based data from the China High Air Pollutants (CHAP) dataset. Cox proportional hazards models were used to estimate the associations between PM2.5 or PM10 and ESRD risk, adjusting for demographic, clinical, and biochemical covariates. Over a median follow-up of 3.63 years, 209 participants progressed to ESRD. Higher exposure to both PM2.5 and PM10 was significantly associated with an increased risk, with hazard ratios of 1.62 and 1.36 per 10 µg/m3 increase, respectively. A nonlinear dose-response relationship was observed, with risk increasing markedly beyond threshold levels. Trajectory modeling of prebaseline exposure identified a subgroup with persistently high and fluctuating particulate matter exposure that showed the highest risk. This study provides strong evidence that prolonged exposure to ambient particulate matter contributes to renal disease progression in individuals with IgAN.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exogenous spexin aggravates renal ischemia reperfusion injury and triggers toxicity in healthy kidneys. 外源性spexin加重肾缺血再灌注损伤并触发健康肾脏的毒性。

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-09-29 DOI: 10.1007/s11684-025-1159-x

Kadri Kulualp, Meltem Kumaş Kulualp, Zeynep Semen, Gökçen Güvenç Bayram, Aslı Çelik, Melek Yeşim Ak, Osman Yilmaz

{"title":"Exogenous spexin aggravates renal ischemia reperfusion injury and triggers toxicity in healthy kidneys.","authors":"Kadri Kulualp, Meltem Kumaş Kulualp, Zeynep Semen, Gökçen Güvenç Bayram, Aslı Çelik, Melek Yeşim Ak, Osman Yilmaz","doi":"10.1007/s11684-025-1159-x","DOIUrl":"https://doi.org/10.1007/s11684-025-1159-x","url":null,"abstract":"Renal ischemia-reperfusion injury (IRI) is a major contributor to acute kidney injury (AKI), leading to substantial morbidity and mortality. Spexin (SPX), a 14-amino acid endogenous peptide involved in metabolic regulation and immune modulation, has not yet been studied in the context of chronic treatment and renal IRI. This study evaluated the effects of exogenous SPX on renal function, histopathological changes, and molecular pathways in both IRI-induced injured and healthy kidneys. Twenty-eight male BALB/c mice were divided into four groups: control, SPX, IRI, and SPX+IRI. IRI was induced by 30 minutes of bilateral renal ischemia followed by 6 hours of reperfusion. Renal injury markers, histopathological changes, inflammatory mediators, apoptotic markers, and fibrosis-related proteins were analyzed. SPX significantly exacerbated IRI-induced kidney injury by activating the Wnt/β-catenin signaling pathway and promoting the upregulation of pro-inflammatory, pro-apoptotic, and pro-fibrotic mediators. It is noteworthy that SPX exerted more severe deleterious nephrotoxic effects in the healthy kidney compared to those observed in the IRI-induced injured kidney. These findings indicate that chronic treatment with SPX administration may have intrinsic pro-inflammatory, pro-apoptotic and fibrotic properties, raising concerns about its therapeutic potential. Further research is needed to clarify its physiological role and therapeutic implications in kidney diseases.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive biomarkers for immunotherapy in nasopharyngeal carcinoma: from tumor microenvironment to macroenvironment. 鼻咽癌免疫治疗的预测性生物标志物：从肿瘤微环境到宏观环境。

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-09-29 DOI: 10.1007/s11684-025-1151-5

Saiwei Huang, Yelin Liang, Na Liu, Jun Ma

引用次数: 0

Global, regional and national burden and trends of congenital musculoskeletal and limb deformities among under-5 children from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. 1990年至2021年5岁以下儿童先天性肌肉骨骼和肢体畸形的全球、区域和国家负担和趋势：对2021年全球疾病负担研究的系统分析

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-09-29 DOI: 10.1007/s11684-025-1156-0

Qinglin Yang, Zhuanmei Jin, Yongping Wang

{"title":"Global, regional and national burden and trends of congenital musculoskeletal and limb deformities among under-5 children from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021.","authors":"Qinglin Yang, Zhuanmei Jin, Yongping Wang","doi":"10.1007/s11684-025-1156-0","DOIUrl":"https://doi.org/10.1007/s11684-025-1156-0","url":null,"abstract":"Congenital musculoskeletal and limb deformities (CMLD) seriously affect the physical and mental health of patients, and pose great challenges to healthcare systems worldwide. We explored the specific situation and changes of incidence, prevalence, disability-adjusted life years rates, and mortality of CMLD in under-5 children from 1990 to 2021 in different groups, including different regions, periods, genders and socio-demographic indices (SDI), through corresponding analytical models. Overall, the global disease burden of CMLD in under-5 children has decreased from 1990 to 2021. The disease burden of CMLD in under-5 children varied significantly among different regions and countries, and there was a strong correlation between the corresponding burden of disease and the level of SDI. In addition, cross-country inequality analysis showed that while absolute inequalities in the disease burden of CMLD in under-5 children have improved, relative inequalities have worsened. It is essential to reduce the global health impact of CMLD by implementing targeted interventions to improve health care in underdeveloped areas.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into potential therapeutic approaches for long COVID. 对长期COVID的潜在治疗方法的见解。

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-09-25 DOI: 10.1007/s11684-025-1149-z

Jingya Zhao, Yingqi Lyu, Jieming Qu

引用次数: 0

Lactate and lactylation in tumor immunity. 乳酸和乳酸化在肿瘤免疫中的作用。

IF 3.5 3区医学

Frontiers of Medicine Pub Date : 2025-09-20 DOI: 10.1007/s11684-025-1148-0

Liu Song, Lingjuan Sun, Song Chen, Peixiang Lan

{"title":"Lactate and lactylation in tumor immunity.","authors":"Liu Song, Lingjuan Sun, Song Chen, Peixiang Lan","doi":"10.1007/s11684-025-1148-0","DOIUrl":"https://doi.org/10.1007/s11684-025-1148-0","url":null,"abstract":"The Warburg effect, originally discovered by Otto Warburg, refers to the metabolic reprogramming of tumor cells from aerobic oxidation to glycolysis, enabling rapid energy production to support their growth and metastasis. This process is accompanied by the massive production and accumulation of lactate both intracellularly and extracellularly. The resulting acidic microenvironment impairs the normal physiological functions of immune cells and promotes tumor progression. An increasing number of studies indicate that lactate, a key metabolite in the tumor microenvironment (TME), acts as a pivotal immunosuppressive signaling molecule that modulates immune cell function. This review aims to comprehensively examine lactate's role as an immunosuppressive molecule in TME. It focuses on mechanisms such as membrane receptor binding, functional reshaping of immune cells via lactate shuttle transport, epigenetic regulation of gene expression through histone lactylation, and modulation of protein structure and function through nonhistone lactylation, emphasizing lactate's importance in immune regulation within the TME. Ultimately, this review offers novel insights into immunosuppressive therapies aimed at targeting lactate function.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0